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Edited by Richard MaraisAbstract Estrogen, which has been strongly implicated in
breast cancer, suppresses apoptosis in estrogen receptor (ER) po-
sitive MCF-7 breast cancer cells. Phospholipase D (PLD), which
is commonly elevated in ER negative breast cancer cells, also
suppresses apoptosis. Survival signals generated by both estrogen
and PLD are dependent upon elevated Myc expression. We
report here that estrogen- and PLD-induced increases in Myc
expression are due to reduced turnover of Myc protein. Estrogen
and PLD suppressed phosphorylation of Myc at Thr58 – a site
that targets Myc for degradation by the proteasome. The data
provide a mechanism for elevated Myc expression in hormone-
dependent and hormone-independent breast cancer.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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GSK-3b1. Introduction
One of the most common defects in human cancer cells is
deregulated expression of the Myc oncogene. Myc is a tran-
scription factor that stimulates the transcription of factors that
facilitate progression through critical cell cycle checkpoints
and suppresses transcription of factors that suppress cell cycle
progression [1]. Elevated Myc expression has been reported in
a wide variety of human cancer [2,3]. Expression of Myc is
regulated at many levels including: transcriptional, post-
transcriptional (mRNA stability and translation), and post-
translational (protein stability) [4–7]. Thus, there are many
ways in which Myc expression can be altered in human can-
cers. In addition, there are mutations to the Myc gene that sig-
niﬁcantly enhance Myc stability and therefore expression [8,9].
Most signiﬁcantly, mutations at Thr58 lead to a stabilized Myc
protein [8,10]. Moreover, phosphorylation of Myc at Thr58
has been shown to regulate Myc stability by targeting Myc
for degradation by the proteasome [11]. Thr58 is phosphory-
lated by glycogen synthase kinase-3b (GSK-3b), which phos-
phorylates many proteins fated for degradation by the
protaseome [12].Abbreviations: CHX, cyclohexamide; E2, 17-b-estradiol; ER, estrogen
receptor; GSK-3b, glycogen synthase kinase-3b; PLD, phospholipase
D; PP2A, protein phosphatase 2A
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doi:10.1016/j.febslet.2006.09.013We reported previously that treatment with 17-b-estradiol
(E2) led to a bi-modal increase in Myc expression in the estro-
gen receptor (ER) positive MCF-7 human breast cancer cell
line [13]. There was a short-term transient increase in Myc
expression that peaked at about two hours. More striking
however was a large sustained stable increase in Myc expres-
sion that peaked at ﬁve days of treatment. This long-term in-
crease in Myc expression was critical for E2 to suppress
apoptosis in MCF-7 cells subjected to the stress of serum with-
drawal [13]. We also reported that elevated phospholipase D
(PLD) activity could suppress apoptosis in MCF-7 cells, and
that PLD similarly increased Myc expression [13,14]. PLD
activity, like Myc expression, has been reported to be elevated
in a substantial percentage of human breast cancers [15,16] and
has been proposed to provide a survival signal in breast and
other cancers [17–19]. Signiﬁcantly, PLD activity is elevated
in several breast cancer cell lines that are ER negative
[14,20–22], suggesting the possibility that elevated PLD activ-
ity in breast cancer cells facilitates progression to hormone
independence. In this report, we provide evidence that the
induction of Myc expression by both E2 and PLD activity is
due to stabilization.2. Materials and methods
2.1. Cells, cell culture conditions and transfection
MCF-7 and MDA-MB-231 cells were obtained from the American
Type Culture Collection and were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with 10% bovine calf serum. Phenol red free
DMEM was employed for experiments as indicated. Cells were trans-
fected with using Lipofectamine 2000 obtained by Invitrogen accord-
ing to the vendor’s instructions. The cells were then selected with
G418 (Invitrogen) over a period of 15 days. Pools of clones were then
collected and used for experiments.2.2. Materials
Cycloheximide, lactacystin and okadaic acid were obtained from
Calbiochem. Polyclonal antibodies to phosphorylated Myc (Thr58),
GSK-3b and phosphorylated GSK-3b (Ser9) were obtained from Cell
Signaling Technology. Antibody to c-Myc and Actin were obtained
from Santa Cruz Biotechnology. The antibody to phosphorylated
Myc (Ser62) was obtained from Anaspec, and a polyclonal rabbit
anti-ubiquitin antibody was obtained from Dako.2.3. Plasmids
The pcDNA3.1 control plasmid was obtained from Invitrogen. The
plasmid expression vector for PLD2 (pCGN-PLD2) and a catalytically
inactive PLD2 mutant (pCGN-PLD2-K758R) [23] were generous gifts
of Dr. Michael Frohman (SUNY-Stony Brook). The pcDNA3.1-
PLD2 constructs containing a neomycin resistance gene were con-
structed as described in [13].blished by Elsevier B.V. All rights reserved.
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The cells were collected as previously described by Hui et al. [24]. The
supernatant was precleared with protein G-Sepharose 4 Fast Flow
beads (Amersham Biosciences), and 500 lg of the precleared proteins
was adjusted to a volume of 500 ll in modiﬁed radioimmune precipita-
tion assay buﬀer and then incubated with the antibody for overnight.
The immunocomplex was captured by incubation with 50 ll of protein
G-Sepharose 4 Fast Flow bead slurry and collected by centrifugation at
12000 · g for 20 s at 4 C. The beads were washed three times with
modiﬁed radioimmune precipitation assay buﬀer and once with wash
buﬀer (50 mMTris, pH 7.6) and then subjected toWestern blot analysis.2.5. Western blot analysis
Extraction of proteins from cultured cells was performed as previ-
ously described [14,20].Fig. 1. E2- and PLD-induced Myc expression is due to suppressed turnove
DMEM with 10% bovine calf serum. After 24 h, the medium was changed to
either 2 h or ﬁve days as indicated. CHX (80 lg/lL) was then added for the i
for the level of Myc protein using Western blot analysis using an anti-Myc a
levels in the cells not treated with CHX (zero time point) were determined by
(B) MCF-7 cells were plated as in (A). 24 h later the medium was changed to
ﬁve days where indicated. At day ﬁve, cells were treated with 10 lM lac
immunoprecipitated with an anti-Myc antibody. Immunoprecipitates were th
(top panel). The lysates were also analyzed for the levels of total Myc by Wes
control for loading. (C) MCF-7V vector control and MCF-7P2 cells, expressi
Cells were treated and analyzed for the level of Myc protein as in (A). (D)
determined as in (B). (E) MDA-MB-231 cells stably transfected with eith
(231P2m) were plated at 2 · 104 cells/60 mm culture dish in DMEM with 10%
free DMEM with 0% serum. Myc levels were determined by Western blot a
independent experiments.3. Results
3.1. E2- and PLD-induced Myc expression is due to
suppressed turnover
We previously reported that E2 enhanced proliferation and
survival of MCF-7 cells subjected to serum withdrawal that
became apparent after ﬁve days [13]. The ability of E2 to
promote proliferation and survival was dependent upon a sus-
tained increase in Myc expression that peaked after ﬁve days of
E2 treatment [13]. The delayed increase of Myc expression oc-
curred without induction of Myc mRNA, indicating that the
increase in Myc expression is not due to an increase in tran-
scription [13]. Since Myc expression is also regulated at ther. (A) MCF-7 cells were plated at 2 · 104 cells/60 mm culture dish in
phenol red free DMEM with 0% serum. E2 (2 nM) was then added for
ndicated times. The cells were then collected and lysates were analyzed
ntibody. The relative Myc protein levels normalized to their respective
using densitometer quantiﬁcation of the data shown in the upper panel.
phenol red-free DMEM without serum. E2 (2 nM) was then added for
tacystin for 6 h at which time cells were collected and lysates were
en subjected to Western blot analysis using an anti-ubiquitin antibody
tern Blot analysis. This blot was reprobed with an antibody to actin to
ng elevated levels of PLD2, were generated as described previously [13].
The levels of ubiquitinated Myc in MCF-7V and MCF-7P2 cells was
er pCDNA3 vector control (231V) or with pcDNA3-PLD2-K758R
bovine calf serum. After 24 h, the medium was changed to phenol red
nalysis 24 h later. The data shown are representative of at least three
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creases in Myc expression were dependent upon protein syn-
thesis. MCF-7 cells were treated with E2 for ﬁve days. The
protein synthesis inhibitor cycloheximide (CHX) was added
to inhibit newly synthesized protein for increasing times out
to 1.5 h. Since E2 also induces a short-term transient increase
in Myc expression that is dependent on an increase in Myc
translation [25], we also examined the eﬀect of CHX on Myc
expression in MCF-7 cells treated with E2 for 2 h. As shown
in Fig. 1A, Myc protein levels induced by E2 for ﬁve days were
very stable in the presence of CHX, whereas the Myc levels in-
duced by E2 at 2 h dropped substantially in the presence of
CHX. These data indicate that the high levels of Myc seen
after ﬁve days of E2 treatment are not aﬀected by inhibition
of protein synthesis, indicating that increased Myc expression
is not due to increased translation.
Since Myc can be degraded via the ubiquitin–proteasome
pathway [8,9], we examined whether long-term E2 treatment
inhibited the ubiquitination of Myc. MCF-7 cells were treated
with E2 for ﬁve days at which time Myc was recovered by
immunoprecipitation. The Myc immunoprecipitates were then
analyzed by Western blot analysis with an anti-ubiquitin anti-
body. As shown in Fig. 1B, E2 reduced the amount of ubiqui-
tinated Myc protein in cell lysates in spite of the fact that there
were highly elevated levels of Myc protein after E2 treatment.
The proteasome inhibitor lactacystin was included to prevent
degradation of ubiquitinated Myc. These data provide evi-
dence that E2 inhibits the ubiquitination of Myc protein,
and consequently, degradation via the ubiquitin/proteasome
pathway.
As observed with E2, elevated PLD activity in MCF-7 cells
also provides a survival signal [14,20] that is dependent upon
elevated expression of Myc [13]. And although E2 did not
stimulate PLD activity, E2-induced Myc expression was
dependent on PLD activity [13]. We therefore extended our
study to MCF-7 cells with elevated expression of PLD2 [13].
As demonstrated previously [13], Myc protein levels are ele-
vated in MCF-7 cells with over-expressed PLD2 (MCF-7P2
cells) relative to MCF-7 vector control cells (MCF-7V cells)
without a corresponding induction of Myc mRNA levels
[13], indicating that increased Myc expression in the MCF-
7P2 cells is not due to increased transcription. We therefore
examined the eﬀect of suppressing protein synthesis on Myc
expression in the MCF-7V and MCF-7 P2 cells. MCF-7V
and MCF-7P2 cells were put in media lacking serum as was
done with the E2 experiments and as reported earlier [13].
CHX was added to the MCF-7V and MCF-7P2 cells and
Myc protein levels were examined at 30 min intervals for
1.5 h. As shown in Fig. 1C, Myc protein levels in the MCF-
7P2 were very stable over this period, whereas Myc levels in
MCF-7V cells dropped substantially during the 1.5 h incuba-
tion period. While the data were obtained using conditions
with prolonged exposure to the serum free media, similar re-
sults were seen at all times of exposure to either low or no ser-
um (not shown). We next examined whether ubiquitination of
Myc was suppressed in the MCF-7P2 cells relative to the
MCF-7V cells. MCF-7V and MCF-7P2 cell lysates were
immunoprecipitated with a Myc antibody and the immuno-
precipitates were then analyzed by Western blot with an
anti-ubiquitin antibody as in Fig. 1B. As shown in Fig. 1D,
ubiquitinated Myc was substantially reduced in the MCF-
7P2 cells relative to the MCF-7V cells. These data provideevidence that overexpression of PLD2 in MCF-7 cells inhibits
ubiquitination of Myc protein and thus its degradation via the
proteasome pathway.
We previously reported that Myc expression is elevated in
MDA-MB-231 cells [20], which have highly elevated PLD
activity that is stimulated by serum withdrawal [21]. We exam-
ined the eﬀect of a catalytically inactive PLD2 mutant that
functions as a dominant negative PLD2 mutant on Myc
expression in these cells and as shown in Fig. 1E, the PLD2
mutant suppressed Myc expression in these cells – further
establishing a link between PLD activity and Myc stability in
breast cancer cells.3.2. E2 and PLD increase phosphorylation of Myc at Ser62
and suppress phosphorylation at Thr58
The ubiquitination and stability of Myc is regulated by
phosphorylation of Myc at two key sites – Ser62 and Thr58.
Phosphorylation at Ser62 by MAP kinase suppresses ubiquiti-
nation and degradation; whereas the phosphorylation at of
Myc at Thr58 by GSK-3b targets Myc for ubiquitination
and degradation [26,27]. Importantly, Ser62 must be phos-
phorylated before GSK-3b can phosphorylate Thr58, and
phosphorylated Ser62 is dephosphorylated by phosphatase-
2A (PP2A) [11]. Dephosphorylation at Ser62 allows degrada-
tion to proceed by removing the stabilizing phosphate at
Ser62. We examined the eﬀect of E2 on the phosphorylation
status of Myc at Ser62 and Thr58. MCF-7 cells were treated
with E2 for ﬁve days and lysates were then analyzed by Wes-
tern blot with antibodies speciﬁc for phosphorylated Myc.
As shown in Fig. 2A, E2 increased phosphorylation Myc at
Ser62 after ﬁve days of treatment compared to the control.
However, total Myc protein was also elevated after E2 treat-
ment. The increased phosphorylation of Ser62 was compared
with increased Myc levels using densitometry scans from sev-
eral experiments and as shown in Fig. 2C, there were higher in-
creases in phosphorylation at Ser62 than observed for total
Myc protein, indicating that there was a net increase in Myc
phosphorylated at Ser62.
We also examined the phosphorylation state of Myc at
Thr58, and as shown in Fig. 2B, E2 strongly reduced the level
of phosphorylated Myc at Thr58 compared to the control. The
reduced levels of Myc phosphorylated at Thr58 were seen in
spite of increased levels of Myc protein. Densitometric analysis
revealed that the suppression of phosphorylation at Thr58 in
response to E2 was more than 20-fold (Fig. 2C). These data re-
veal that E2 suppresses phosphorylation at Thr58 – a site that
when phosphorylated, targets Myc for ubiquitination and deg-
radation [26,27]. In addition, the data also reveal that E2 also
increases phosphorylation at Ser62 – a site that suppresses
ubiquitination and degradation [11]. While the eﬀect of E2
on the phosphorylation at Ser62 was reproducible, the eﬀect
on phosphorylation at Thr58 was far more dramatic. These
data support the hypothesis that the elevated Myc expression
in response to E2 is due to stabilization through elevated phos-
phorylation of Ser62 and reduced phosphorylation at Thr58.
The eﬀect of elevated PLD2 expression on the phosphoryla-
tion of Myc at Ser62 and Thr58 in MCF-7 cells was also exam-
ined. As shown in Fig. 2D, PLD2 over-expression also resulted
in increased phosphorylation of Myc at Ser62. As observed
with E2 treatment, total Myc was elevated in the MCF-7P2
cells relative to the MCF-7V cells. However, as observed with
Fig. 2. E2 and PLD increase phosphorylation of Myc at Ser62 and suppress phosphorylation at Thr58. (A) MCF-7 cells were prepared and collected
as described in Fig. 1 and placed in serum-free, phenol red-free DMEM with or without E2 (2 nM) as indicated. Lysates were prepared and analyzed
for the levels of phosphorylated Myc protein at Ser62 by Western blot analysis with an antibody against Myc phosphorylated at this site (Anaspec).
The blot was stripped and reprobed with an antibody to total Myc protein. The blot was also reprobed with an antibody to actin to control for
loading. (B) MCF-7 cells were treated and collected as in (A) and the lysates were analyzed for the levels of phosphorylated Myc protein at Thr58
using an antibody that recognizes Myc phosphorylated at this site. The blot was stripped and reprobed with antibodies to Myc and actin as in (A).
(C) The levels of phosphorylated Myc in presence of E2 were normalized to their respective levels in the untreated control was determined using
densitometer quantiﬁcation. The relative changes in phosphorylated Myc for both Sre62 and Thr58 were compared to level of total Myc protein. (D)
MCF-7V and MCF-7P2 cells were prepared and collected as described in (A) and placed in phenol red-free DMEM with 0.5% serum. Lysates were
prepared ﬁve days later and analyzed by Western blot for the level of Myc phosphorylated at Ser62 (D) and Thr58 (E) as in (A) and (B) respectively.
(F) The levels of phosphorylated Myc in the MCF-7P2 cells were normalized to the level in the MCF-7V was determined using densitometer
quantiﬁcation. The relative changes in phosphorylated Myc for both Ser62 and Thr58 were compared to level of total Myc protein. Experiments
shown in (A), (B), (D) and (E) are representative of three independent experiments. The data in (C) and (F) are the averages of three independent
experiments normalized to the levels of Myc protein. Error bars represent the standard deviation.
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phorylated at Ser62 than observed for total Myc protein in
the MCF-7P2 cells. Densitometric analysis indicated a 50%
increase in Myc phosphorylated at Ser62 (Fig. 2F). The phos-
phorylation state of Myc at Thr58 in MCF-7V and MCF-7P2
cells was also examined, and as shown in Fig. 2E, the level of
phosphorylated Myc at Thr58 in MCF-7P2 cells was dramat-
ically reduced relative to the MCF-7V cells. Densitometric
analysis revealed that the suppression of phosphorylation at
Thr58 in response to PLD over-expression was more than
50-fold (Fig. 2F). These data reveal that PLD, like E2, strongly
suppresses phosphorylation at Thr58 and increases phosphor-
ylation at Ser62 – supporting the hypothesis that the increase
in Myc levels is due to stabilization.
3.3. E2 and PLD induce phosphorylation of GSK-3 b at the
negative regulatory site Ser9
Since the eﬀect of E2 on phosphorylation at Thr58 was so
dramatic, we examined the eﬀect of E2 on GSK-3b. GSK-3b
is a ubiquitous protein kinase that is inhibited by phosphory-
lation at Ser9 [28–30]. E2 was previously reported to inhibit
GSK-3b in the hippocampus [31]. We therefore examined the
eﬀect of E2 on the phosphorylation of GSK-3b at Ser9.
MCF-7 cells were treated with E2 for ﬁve days and lysateswere then analyzed by Western blot using an antibody that rec-
ognizes GSK-3b phosphorylated at Ser9. As shown in Fig. 3A,
the ﬁve-day treatment with E2 led to a large increase in the
phosphorylation of GSK-3b at Ser9. The total GSK-3b pro-
tein level was not aﬀected by E2 treatment. We then examined
whether PLD, like E2, induced an increase in the phosphory-
lation of the negative regulatory site Ser9. MCF-7V control
or MCF-7P2 cells lysates were analyzed by Western blot anal-
ysis with the anti-Ser9 GSK-3b antibody. As shown in Fig. 3B,
PLD2 over-expression substantially increased phosphorylation
of GSK-3b at Ser9 relative to the MCF-7V control cells. Total
GSK-3b protein levels were not aﬀected by PLD2. These data
indicate that both E2 and elevated PLD expression can result
in the inhibition of GSK-3b by increasing phosphorylation of
GSK-3b at Ser9.4. Discussion
Suppression of apoptosis is critical in tumor progression
[32]. Myc has been implicated in the suppression of apoptosis
and progression past cell cycle checkpoints where apoptosis is
regulated [3]. The regulation of Myc expression is complex and
is controlled at the level of transcription, translation and
Fig. 3. E2 induces phosphorylation of GSK-3b at the negative
regulatory site Ser9. (A) MCF-7 cells were prepared as described in
Fig. 1 and placed in serum-free phenol red-free DMEM in the absence
or presence of E2 (2 nM) for ﬁve days as indicated. Lysates were
prepared and analyzed for the levels of phospho-GSK-3b (Ser9) by
Western blot analysis using an antibody that recognizes GSK-3b
phosphorylated at this site (Cell Signaling Technology). The blot was
stripped and reprobed for the levels of total GSK-3b protein. The blot
was reprobed with an antibody to actin to control for loading. (B)
MCF-7V and MCF-7P2 cells were prepared as in (A) and placed in
phenol red-free DMEM with 0.5% serum. Lysates were prepared ﬁve
days later and analyzed for the levels of phospho-GSK-3b (Ser9)
protein as in (A). The data shown are representative of three
independent experiments.
Fig. 4. Model for Myc stabilization in response to E2 and PLD. MAP
kinase (MAPK) phosphorylates Myc at Ser62 (S62-P), which stabilizes
Myc. Myc, phosphorylated at Ser62, can then be phosphorylated at
Thr58 (T58-P) by GSK-3b. The doubly phosphorylated Myc can then
be dephosphorylated at Ser62 by PP2A. Myc phosphorylated only at
Thr58 is recognized by a ubiquitin (Ub) ligase that leads to the
ubiquitination of Myc and degradation by the proteasome [33]. Both
E2 and PLD can suppress ubiquitination and degradation by
suppressing the GSK-3b phosphorylation of Myc at Thr58. In
addition, PLD can also suppress the PP2A [24]. The eﬀect of E2 and
PLD on Myc is the stabilization of Myc, which is required for the
survival signals generated by both E2 and PLD [13].
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sure to E2 leads to very high levels of Myc expression that
peaked at ﬁve days and that elevated Myc expression was re-
quired for the suppression of apoptosis in ER positive MCF-
7 cells subjected to the stress of serum withdrawal [13]. E2
could be replaced with elevated PLD expression, which simi-
larly increased Myc expression and suppressed apoptosis in
MCF-7 cells subjected to serum withdrawal. In this report,
we have characterized the mechanism for the sustained induc-
tion of Myc. We found that the increased Myc expression in-
duced by both E2 and PLD was due to stabilization. Both
E2 and PLD suppressed phosphorylation of Myc at Thr58 –
a site that targets Myc for degradation by the proteasome
[8,34]. Myc is phosphorylated at Thr58 by GSK-3b [26,27],
and consistent with the reduced phosphorylation of Myc at
Thr58, both E2 and PLD stimulated a substantial increase in
the phosphorylation of GSK-3b at Ser9, which suppresses
GSK-3b activity [28–30]. A model for the E2 and PLD stabil-
ization of Myc through suppression of GSK-3b is shown sche-
matically in Fig. 4.
The phosphorylation of Myc at Ser62 was elevated in re-
sponse to both E2 and PLD. The eﬀect was not as dramatic
as observed for Thr58, but the increased phosphorylation at
Ser62 is also consistent with increased stability of Myc. Myc
must be ﬁrst phosphorylated at Ser62 before it can be phos-
phorylated at Thr58 [11], and then it must subsequently be
dephosphorylated by PP2A before it can be ubiquitinated.
Consistent with this model we previously reported that PLD
activity suppresses PP2A activity in MCF-7 cells [24]. Thus,
the increased phosphorylation of Myc at Ser62 in response
to PLD likely reﬂects the suppression of PP2A activity by
PLD. We did not see a signiﬁcant eﬀect of E2 on PP2A activityin the MCF-7 cells. Thus, at this time we are not sure as to how
E2 increases phosphorylation of Myc at Ser62.
We have proposed that elevated PLD activity in human
breast cancer provides a means for progression to hormone
independence [17]. This was largely based on the observation
that breast cancer cell lines with highly elevated PLD activity
were all ER negative and most breast cancer cell lines with
low PLD activity were ER negative [13,14,20–22]. While these
observations only provide correlative evidence for the involve-
ment PLD in progression to hormone independence in breast
cancer, there is increasing evidence that PLD generates sur-
vival signals that would compensate for the loss of hormone
responsiveness and dependence. As we reported previously,
and observed by others, E2 provides a survival signal in ER
positive breast cancer cells [13,34–36]. PLD similarly provides
a survival signal in breast cancer cells subjected to the stress of
serum withdrawal [14,22], conditions that occur in an emerging
solid tumor prior to vascularization. The lack of serum would
also restrict access to E2 and select for cells that could survive
these conditions. Cells with elevated PLD activity would have
the ability to survive these conditions. The ﬁnding here that
PLD, like E2 can promote the stabilization of Myc further
supports a critical role for the elevated PLD activity commonly
seen in ER negative breast cancer cells for survival as tumors
progress to hormone independence. The study suggests that
in hormone resistant breast cancers, targeting PLD survival
signals could be an eﬀective therapeutic strategy for inducing
apoptosis in breast cancer cells dependent on PLD activity
for survival.
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